AT7519 achieves direct CDK inhibition in Ph I trial

UK biotechnology firm Astex Therapeutics says that positive biomarker data from the first Phase I trial of its cyclin dependent kinase  inhibitor, AT7519, will be presented at the American Association for  Cancer Research annual meeting, in Denver, Colorado.

Results to be reported at this meeting demonstrate that direct  inhibition of CDK was observed in skin biopsies or serum samples at all  doses during the escalation phase. By monitoring phenotypic markers that  occur only as a consequence of a pharmacologically-relevant CDK  inhibition, the firm was further able to determine a predicted  biologically-effective dose.